A Mesenchymal Glioma Stem Cell Profile Is Related to Clinical Outcome
Comparative analysis between glioma stem cells (GSCs) and H1 and H9 human embryonic stem cells as well as H9-derived neural stem cells indicates major variations in gene expression of pluripotency factors Nanog and OCT4, but a stable pattern for SOX2 suggesting its important function in maintaining pluripotency in GSCs. [Oncogenesis]
Full Article
REVIEWS
The Paradigm of Mutant p53-Cancer Stem Cells and Drug Resistance
The notion that p53 plays a regulatory role in the life of stem cells coupled with the observations that p53 mutations may contribute to the evolvement of cancer stem cells, makes it challenging to speculate that drug resistance and cancer recurrence are mediated by cancer stem cells expressing mutant p53. [Carcinogenesis]
Abstract
Glioblastoma Cancer Stem Cells: Biomarker and Therapeutic Advances
Basic glioblastoma multiforme and glioblastoma cancer stem cell (GSC) genetics and proteomics studies combined with strategies to discover GSC-targeting agents could lead to novel treatments that significantly improve patient survival and quality of life. [Neurochem Int]
Abstract
Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.
INDUSTRY NEWS
NRC and Zymeworks Partner to Develop Ground-Breaking Canadian Therapies for the Fight against Cancer
The National Research Council of Canada (NRC) and Zymeworks Inc. announced a strategic collaborative agreement for a continued innovative business alliance. This three-year multi-million dollar agreement will focus on developing ground-breaking therapies for the fight against cancer, as well as inflammatory and autoimmune diseases. [Zymeworks Inc.]
Press Release
MultiCell Technologies Files U.S. and International Patent Applications for the Treatment of Liver Cancer
MultiCell Technologies, Inc. has filed additional U.S. and international patent applications covering MCT-485 and its composition of matter, biological targets, mechanism of action, and methods and formulations for therapeutic use. MCT-485 is thought to target cancer by delivering a cytotoxic and oncolytic effect to only those cells having the highest tumor initiating capability that are part of the cancerous process such as cancer stem cells and tumor initiating cells. [PR Newswire Association LLC]
Press Release
Recruit Top Talent: Reach more than 50,000 potential candidates by posting
your organization’s career opportunities on the Connexon Creative Job Board at no cost.
Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!